© Reuters.
Los Angeles-based biotech firm, Renovaro Biosciences, saw its shares surge by 17% on Tuesday following the appointment of Leni Boeren and Ruud Hendriks as independent directors. The announcement comes ahead of the company’s proposed merger with AI firm GEDi Cube.
Boeren and Hendriks are expected to bring significant financial insights to Renovaro Biosciences. Boeren has an extensive 40-year history in finance, with roles at Paribas, Rabobank, Euronext, and as CEO of Robeco Groep. Hendriks also brings a wealth of experience from his 35 years at Goldman Sachs Asset Management and as an adviser to KKR.
The company’s Chairman, Rene Sindlev, anticipates that the new directors’ contributions will be instrumental in continuing the positive trajectory towards commercialization. This year has seen a quadrupling of Renovaro’s share price, a trend that the company aims to maintain and build upon with these strategic appointments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
This story originally appeared on Investing
